These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11410497)

  • 1. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
    Kang MH; Figg WD; Ando Y; Blagosklonny MV; Liewehr D; Fojo T; Bates SE
    Clin Cancer Res; 2001 Jun; 7(6):1610-7. PubMed ID: 11410497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma using column-switching liquid chromatography/tandem mass spectrometry.
    Yamaguchi H; Fujikawa A; Ito H; Tanaka N; Furugen A; Miyamori K; Takahashi N; Ogura J; Kobayashi M; Yamada T; Mano N; Iseki K
    Biomed Chromatogr; 2013 Apr; 27(4):539-44. PubMed ID: 23018973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
    Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
    Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN; Gréen H; Litton JE; Friberg LE
    Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions of paclitaxel metabolism in human liver microsomes.
    Bun SS; Ciccolini J; Bun H; Aubert C; Catalin J
    J Chemother; 2003 Jun; 15(3):266-74. PubMed ID: 12868554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human liver microsomal metabolism of paclitaxel and drug interactions.
    Desai PB; Duan JZ; Zhu YW; Kouzi S
    Eur J Drug Metab Pharmacokinet; 1998; 23(3):417-24. PubMed ID: 9842986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.
    Václavíková R; Horský S; Simek P; Gut I
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):200-9. PubMed ID: 12920504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface.
    Gréen H; Vretenbrant K; Norlander B; Peterson C
    Rapid Commun Mass Spectrom; 2006; 20(14):2183-9. PubMed ID: 16791868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
    Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in human cytochrome P450 paclitaxel metabolism.
    Sonnichsen DS; Liu Q; Schuetz EG; Schuetz JD; Pappo A; Relling MV
    J Pharmacol Exp Ther; 1995 Nov; 275(2):566-75. PubMed ID: 7473140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.
    Royer I; Monsarrat B; Sonnier M; Wright M; Cresteil T
    Cancer Res; 1996 Jan; 56(1):58-65. PubMed ID: 8548776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.
    Vaclavikova R; Soucek P; Svobodova L; Anzenbacher P; Simek P; Guengerich FP; Gut I
    Drug Metab Dispos; 2004 Jun; 32(6):666-74. PubMed ID: 15155559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of paclitaxel in mice.
    Bardelmeijer HA; Oomen IA; Hillebrand MJ; Beijnen JH; Schellens JH; van Tellingen O
    Anticancer Drugs; 2003 Mar; 14(3):203-9. PubMed ID: 12634614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
    Monsarrat B; Royer I; Wright M; Cresteil T
    Bull Cancer; 1997 Feb; 84(2):125-33. PubMed ID: 9180834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
    Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
    Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
    Huizing MT; Sparreboom A; Rosing H; van Tellingen O; Pinedo HM; Beijnen JH
    J Chromatogr B Biomed Appl; 1995 Dec; 674(2):261-8. PubMed ID: 8788155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    van Zuylen L; Sparreboom A; van der Gaast A; van der Burg ME; van Beurden V; Bol CJ; Woestenborghs R; Palmer PA; Verweij J
    Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM; Westervelt P; Fears CL; Rosen DM; Zuhowski EG; Cazenave LA; Litchman M; Egorin MJ
    J Clin Oncol; 2000 Mar; 18(5):1124-34. PubMed ID: 10694566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.